Clinical Trials

SARS-CoV-2 antibody after COVID-19 vaccination in patients with multiple sclerosis

Type of Study/Intervention

Prospective cohort study

Recruitment Status

Recruiting

Form of MS

Relapsing remitting MS/Secondary progressive MS/Primary progressive MS/ Relapsing MS

Brief summary

COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to determine the COVID-19 vaccine immunogenicity and to assess the protection given by vaccines in people living with MS.

Inclusion criteria

– Diagnosed Multiple Sclerosis according to 2017 McDonald criteria
– Treatment by any TGA-approved Disease Modifying Therapy (DMT) for MS, e.g. ocrelizumab, alemtuzumab, natalizumab, fingolimod, cladribine, beta-interferon, copaxone, dimethylfumarate, ofatumumab, siponimod, glatiramer acetate.
– Recipient of COVID-19 vaccine (Pfizer, Astra Zeneca, or Novavax).
– Is able to give consent

Exclusion criteria

Non-English speaking

Anticipated start date

May 2021

Recruitment contacts

Fabienne Brilot-Turville, fabienne.brilot@sydney.edu.au

Region

NSW/VIC/QLD/WA

Ethics approval

Yes

Last updated

21/06/2021

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search